MCID: CRB138
MIFTS: 43

Core Binding Factor Acute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

MalaCards integrated aliases for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 25 17 71
Cbf Acute Myeloid Leukemia 25
Core-Binding Factor Aml 25
Cbf-Aml 25

Classifications:



External Ids:

UMLS 71 C3839741

Summaries for Core Binding Factor Acute Myeloid Leukemia

Genetics Home Reference : 25 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets. People with CBF-AML have a shortage of all types of mature blood cells: a shortage of white blood cells (leukopenia) leads to increased susceptibility to infections, a low number of red blood cells (anemia) causes fatigue and weakness, and a reduction in the amount of platelets (thrombocytopenia) can result in easy bruising and abnormal bleeding. Other symptoms of CBF-AML may include fever and weight loss. While acute myeloid leukemia is generally a disease of older adults, CBF-AML often begins in young adulthood and can occur in childhood. Compared to other forms of acute myeloid leukemia, CBF-AML has a relatively good prognosis: about 90 percent of individuals with CBF-AML recover from their disease following treatment, compared with 25 to 40 percent of those with other forms of acute myeloid leukemia. However, the disease recurs in approximately half of them after successful treatment of the initial occurrence.

MalaCards based summary : Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to cytogenetically normal acute myeloid leukemia and mastocytosis. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fludarabine and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 cytogenetically normal acute myeloid leukemia 30.3 WT1 FLT3 CEBPA
2 mastocytosis 30.2 KIT JAK2 FLT3 CBL
3 systemic mastocytosis 30.1 NRAS KIT JAK2
4 childhood acute myeloid leukemia 29.3 WT1 NRAS KIT HRAS FLT3 ABCG2
5 sarcoma 28.6 WT1 NRAS KRAS KIT JAK2 HRAS
6 acute leukemia 28.1 WT1 RUNX1 MVP KRAS KIT JAK2
7 leukemia 27.7 WT1 RUNX2 RUNX1 NRAS KRAS KIT
8 myeloid leukemia 27.4 WT1 RUNX2 RUNX1 NRAS KRAS KIT
9 myelodysplastic syndrome 26.9 WT1 RUNX1 NRAS KRAS KIT JAK2
10 leukemia, acute myeloid 26.6 WT1 RUNX2 RUNX1 NRAS MVP KRAS
11 acute myeloblastic leukemia with maturation 10.5 KIT FLT3
12 signet ring basal cell carcinoma 10.4 KRAS HRAS
13 trachea carcinoma in situ 10.4 KRAS HRAS
14 thymoma, familial 10.4 KIT HRAS
15 cobblestone retinal degeneration 10.4 KRAS HRAS
16 nasal cavity adenocarcinoma 10.4 KRAS HRAS
17 ampulla of vater neoplasm 10.4 KRAS HRAS
18 descending colon cancer 10.4 KRAS HRAS
19 periampullary adenoma 10.4 KRAS HRAS
20 8p11 myeloproliferative syndrome 10.4 RUNX1 KIT FLT3
21 adenosquamous lung carcinoma 10.4 KRAS HRAS
22 transverse colon cancer 10.3 KRAS HRAS
23 appendiceal neoplasm 10.3 KRAS HRAS
24 gallbladder benign neoplasm 10.3 KRAS HRAS
25 myh-associated polyposis 10.3 KRAS HRAS
26 appendix adenocarcinoma 10.3 KRAS HRAS
27 mucinous lung adenocarcinoma 10.3 KRAS HRAS
28 biliary tract benign neoplasm 10.3 KRAS HRAS
29 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.3 KIT JAK2
30 chromosomal triplication 10.3
31 trisomy 22 10.3
32 sm-ahnmd 10.3 KIT JAK2
33 acute erythroid leukemia 10.3 JAK2 CEBPA
34 testicular gonadoblastoma 10.3 WT1 KIT
35 tumor of exocrine pancreas 10.3 KRAS HRAS
36 uterine sarcoma 10.3 WT1 KIT
37 colon leiomyosarcoma 10.3 WT1 KIT
38 pancreatic acinar cell adenocarcinoma 10.3 KRAS HRAS
39 uterine body mixed cancer 10.2 KRAS KIT HRAS
40 ovarian mixed germ cell neoplasm 10.2 WT1 KIT
41 retinitis pigmentosa and erythrocytic microcytosis 10.2 JAK2 CSF3
42 hypereosinophilic syndrome, idiopathic 10.2 WT1 KIT
43 refractory anemia 10.2 RUNX1 CSF3
44 pyogenic granuloma 10.2 NRAS KRAS
45 liver leiomyosarcoma 10.2 WT1 KIT
46 lung carcinoma in situ 10.2 KRAS HRAS
47 ovarian gonadoblastoma 10.2 WT1 KIT
48 appendix disease 10.2 KRAS HRAS
49 large cell carcinoma 10.2 KRAS KIT HRAS
50 atypical chronic myeloid leukemia 10.2 RUNX1 JAK2 FLT3

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to Core Binding Factor Acute Myeloid Leukemia

Symptoms & Phenotypes for Core Binding Factor Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show top 50) (show all 95)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 10.82 CBFB
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.82 FLT3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.82 CBFB
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.82 KRAS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 10.82 NRAS
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.82 CBL
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.82 KRAS
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.82 FLT3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.82 CEBPA FLT3
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.82 CBL CEBPA FLT3 CBFB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.82 FLT3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 10.82 NRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-13 10.82 CBFB
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.82 CBL CEBPA FLT3 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.82 CBL CEBPA NRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 10.82 NRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.82 FLT3
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.82 KRAS
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.82 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.82 CBFB
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.82 FLT3
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.82 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.82 CBFB
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.82 FLT3
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.82 KRAS
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.82 KRAS
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.82 CEBPA CBFB NRAS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-208 10.82 NRAS
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.82 KRAS
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.82 KRAS WT1
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.82 KRAS
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.82 NRAS
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.82 KRAS
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.82 CSF3
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-35 10.82 WT1
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.82 CBL
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.82 CBL CEBPA
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-45 10.82 CSF3
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.82 KRAS
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.82 KRAS
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.82 KRAS
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 10.82 NRAS
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-6 10.82 CSF3
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 10.82 NRAS
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.82 KRAS
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 10.82 CEBPA CBFB
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.82 KRAS
48 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.33 WT1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.33 CSF3
50 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.33 FLT3

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 ABCG2 CBFB CBL CEBPA CSF1R FLT3
2 hematopoietic system MP:0005397 10.37 ABCG2 CBFB CBL CEBPA CSF1R CSF3
3 endocrine/exocrine gland MP:0005379 10.36 CBFB CBL CEBPA CSF1R FLT3 HRAS
4 homeostasis/metabolism MP:0005376 10.36 ABCG2 CBFB CBL CEBPA CSF1R FLT3
5 growth/size/body region MP:0005378 10.35 CBFB CBL CEBPA CSF1R FLT3 HRAS
6 immune system MP:0005387 10.34 ABCG2 CBFB CBL CEBPA CSF1R CSF3
7 cardiovascular system MP:0005385 10.32 CBFB CBL CEBPA HRAS JAK2 KIT
8 integument MP:0010771 10.29 ABCG2 CBFB CBL CEBPA CSF1R CSF3
9 mortality/aging MP:0010768 10.22 CBFB CBL CEBPA CSF1R FLT3 HRAS
10 craniofacial MP:0005382 10.17 CBFB CBL CSF1R HRAS KIT KRAS
11 liver/biliary system MP:0005370 10.17 ABCG2 CBFB CBL CEBPA JAK2 KIT
12 digestive/alimentary MP:0005381 10.1 CBFB CEBPA HRAS KIT KRAS NRAS
13 neoplasm MP:0002006 10.07 CBFB CEBPA FLT3 HRAS JAK2 KIT
14 no phenotypic analysis MP:0003012 10.06 CBFB CEBPA CSF1R FLT3 HRAS KIT
15 normal MP:0002873 10.03 ABCG2 CBFB CEBPA CSF1R HRAS JAK2
16 limbs/digits/tail MP:0005371 10 CBFB CBL CSF1R KIT KRAS NRAS
17 renal/urinary system MP:0005367 9.7 ABCG2 CEBPA CSF3 HRAS KIT KRAS
18 respiratory system MP:0005388 9.65 CBFB CBL CEBPA HRAS JAK2 KIT
19 skeleton MP:0005390 9.36 CBFB CBL CSF1R FLT3 HRAS JAK2

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
2
Lenograstim Approved, Investigational Phase 2 135968-09-1
3
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
4
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
5
Etoposide Approved Phase 2 33419-42-0 36462
6
Busulfan Approved, Investigational Phase 2 55-98-1 2478
7
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
8
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
9
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
10
Daunorubicin Approved Phase 1, Phase 2 20830-81-3 30323
11
Cytarabine Approved, Experimental, Investigational Phase 1, Phase 2 147-94-4, 65-46-3 6253
12
midostaurin Approved, Investigational Phase 1, Phase 2 120685-11-2 104937 9829523
13 Molgramostim Investigational Phase 2 99283-10-0
14
Alvocidib Experimental, Investigational Phase 2 131740-09-5, 146426-40-6 5287969
15 Staurosporine Experimental Phase 1, Phase 2 62996-74-1
16 Etoposide phosphate Phase 2
17 Adjuvants, Immunologic Phase 2
18 Analgesics Phase 2
19 Alkylating Agents Phase 2
20 Tubulin Modulators Phase 2
21 Dermatologic Agents Phase 2
22 Podophyllotoxin Phase 2 518-28-5
23 Keratolytic Agents Phase 2
24 Antimitotic Agents Phase 2
25 Protein Kinase Inhibitors Phase 1, Phase 2
26 Immunologic Factors Phase 1, Phase 2
27 Anti-Infective Agents Phase 1, Phase 2
28 Antiviral Agents Phase 1, Phase 2
29 Immunosuppressive Agents Phase 1, Phase 2
30 Anti-Bacterial Agents Phase 1, Phase 2
31 Antibiotics, Antitubercular Phase 1, Phase 2
32 Antimetabolites Phase 1, Phase 2
33 Gemtuzumab Phase 1, Phase 2
34 Iron-Dextran Complex Phase 1, Phase 2
35 Antineoplastic Agents, Immunological Phase 1, Phase 2
36
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
37 Aclacinomycins

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
2 A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
3 Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Recruiting NCT02013648 Phase 3 Dasatinib;Cytarabine;Daunorubicin;Idarubicin
4 Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00850382 Phase 1, Phase 2 Dasatinib;daunorubicin;Cytarabine
5 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
6 Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML &lt; 60 Years Completed NCT00416598 Phase 2 Busulfan;Cytarabine;Daunorubicin Hydrochloride;Decitabine;Etoposide
7 Prospective Evaluation of a Continuation Therapy With Midostaurin in Adult Patients With Core-binding Factor Leukemia and Integrated Genetic Analysis: a Multi-center Phase II Study Recruiting NCT03686345 Phase 2 Midostaurin
8 Efficacy and Safety of Chidamide in CBF Leukemia Recruiting NCT03031262 Phase 1, Phase 2 Cytarabine;Chidamide
9 A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML) Active, not recruiting NCT01238211 Phase 2 Cytarabine;Dasatinib;Daunorubicin Hydrochloride
10 Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring Active, not recruiting NCT02971397 Phase 2 Cytarabine;Daunorubicin Hydrochloride
11 MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Not yet recruiting NCT04385290 Phase 1, Phase 2 MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO;MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO;MAGNOLIA-trial: Placebo associated with conventional chemotherapy (AraC+DNR)+GO;MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin;MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin
12 Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401) Withdrawn NCT02680951 Phase 1 Dasatinib;Fludarabine;Cytarabine;Idarubicin;Intrathecal (IT) cytarabine
13 Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia Unknown status NCT01066286
14 The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China Recruiting NCT03173612 Dasatinib
15 Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission Recruiting NCT01050036

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

40
Myeloid, Bone Marrow, Bone, Eye

Publications for Core Binding Factor Acute Myeloid Leukemia

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50) (show all 152)
# Title Authors PMID Year
1
Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation. 61
32229198 2020
2
Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. 61
32249963 2020
3
The increasing complexity of the management of core-binding factor acute myeloid leukemia. 61
32482754 2020
4
Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience. 61
32496446 2020
5
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. 61
32561839 2020
6
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 61
31439677 2020
7
AML: New Drugs but New Challenges. 61
32151586 2020
8
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. 61
32101640 2020
9
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. 61
32461631 2020
10
[Efficacy and prognostic factors in children with non-core binding factor acute myeloid leukemia]. 61
32434642 2020
11
Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia. 61
32419364 2020
12
Cytological and spectroscopic characteristics of c-KIT N822K mutation in core binding factor acute myeloid leukemia cells. 61
32390317 2020
13
Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. 61
32175599 2020
14
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. 61
32092139 2020
15
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. 61
31899799 2020
16
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. 61
31896684 2020
17
[The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia]. 61
32008291 2020
18
Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia. 61
31796871 2019
19
[A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia]. 61
31665853 2019
20
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells. 61
31484543 2019
21
[Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia]. 61
31302905 2019
22
Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. 61
31311917 2019
23
Different prognostic effects of core-binding factor positive AML with Korean AML registry data. 61
30758645 2019
24
Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML. 61
31040112 2019
25
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. 61
30089916 2019
26
[Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia]. 61
30704229 2019
27
Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death. 61
31217744 2019
28
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study. 61
30082223 2018
29
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). 61
30117318 2018
30
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. 61
29692343 2018
31
Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation. 61
29950292 2018
32
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. 61
29720733 2018
33
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. 61
29991495 2018
34
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. 61
29705537 2018
35
Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. 61
29500710 2018
36
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine. 61
29719925 2018
37
KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. 61
28792268 2018
38
[Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia]. 61
30305502 2018
39
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. 61
29107583 2018
40
Detection of KIT mutations in core binding factor acute myeloid leukemia. 61
30112273 2018
41
SNP-array lesions in core binding factor acute myeloid leukemia. 61
29464086 2018
42
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. 61
27597292 2017
43
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. 61
28233452 2017
44
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. 61
28762080 2017
45
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. 61
28556489 2017
46
Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet? 61
28654205 2017
47
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. 61
29071049 2017
48
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. 61
28494506 2017
49
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. 61
28506695 2017
50
Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia. 61
28439893 2017

Variations for Core Binding Factor Acute Myeloid Leukemia

Expression for Core Binding Factor Acute Myeloid Leukemia

Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for Core Binding Factor Acute Myeloid Leukemia

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 NRAS MVP KRAS KIT JAK2 HRAS
2
Show member pathways
13.85 NRAS KRAS KIT JAK2 HRAS FLT3
3
Show member pathways
13.7 NRAS KRAS KIT JAK2 HRAS FLT3
4
Show member pathways
13.57 NRAS KRAS KIT JAK2 HRAS FLT3
5
Show member pathways
13.33 NRAS KRAS KIT JAK2 HRAS CSF3
6
Show member pathways
13.31 NRAS KRAS KIT JAK2 HRAS FLT3
7
Show member pathways
13.25 TLE1 NRAS KRAS KIT HRAS FLT3
8
Show member pathways
13.22 NRAS KRAS KIT JAK2 HRAS FLT3
9
Show member pathways
13.08 NRAS KRAS KIT JAK2 HRAS CSF1R
10
Show member pathways
12.93 NRAS KRAS JAK2 HRAS CBL
11
Show member pathways
12.84 NRAS KRAS JAK2 HRAS CBL
12
Show member pathways
12.84 NRAS KRAS KIT JAK2 HRAS FLT3
13
Show member pathways
12.8 NRAS KRAS KIT JAK2 HRAS CBL
14
Show member pathways
12.77 NRAS KRAS KIT HRAS CBL
15 12.76 NRAS KRAS KIT HRAS FLT3 CSF1R
16
Show member pathways
12.73 NRAS KRAS KIT HRAS FLT3 CSF1R
17
Show member pathways
12.65 NRAS KRAS JAK2 HRAS CBL
18
Show member pathways
12.63 NRAS KRAS JAK2 HRAS CBL
19
Show member pathways
12.61 NRAS KRAS JAK2 HRAS
20
Show member pathways
12.61 NRAS KRAS HRAS CBL
21 12.6 RUNX1 KIT JAK2 CEBPA CBL
22
Show member pathways
12.58 NRAS KRAS HRAS CBL
23
Show member pathways
12.57 TLE1 RUNX2 JAK2 CBL
24
Show member pathways
12.54 NRAS KRAS HRAS CBL
25
Show member pathways
12.53 NRAS KRAS JAK2 HRAS CBL
26
Show member pathways
12.52 NRAS KRAS HRAS CBL
27
Show member pathways
12.5 NRAS KRAS JAK2 HRAS CBL
28
Show member pathways
12.48 NRAS KRAS HRAS CBL
29
Show member pathways
12.45 NRAS KRAS HRAS CBL
30
Show member pathways
12.44 NRAS KRAS HRAS CBL
31
Show member pathways
12.44 NRAS KRAS KIT HRAS
32
Show member pathways
12.43 JAK2 HRAS CEBPA CBL
33
Show member pathways
12.4 NRAS KRAS JAK2 HRAS CSF3 CSF1R
34
Show member pathways
12.39 NRAS KRAS HRAS FLT3 CBL
35
Show member pathways
12.36 RUNX1 NRAS KRAS KIT HRAS FLT3
36 12.35 NRAS KRAS HRAS CBL
37
Show member pathways
12.34 NRAS KRAS JAK2 HRAS
38
Show member pathways
12.34 NRAS KRAS JAK2 HRAS
39
Show member pathways
12.32 NRAS KRAS HRAS CBL
40
Show member pathways
12.27 NRAS KRAS KIT HRAS FLT3 CSF1R
41
Show member pathways
12.25 NRAS KRAS HRAS CSF1R
42
Show member pathways
12.24 NRAS KRAS JAK2 HRAS CBL
43 12.23 KRAS JAK2 HRAS CBL
44
Show member pathways
12.22 KIT JAK2 HRAS CBL
45
Show member pathways
12.18 NRAS KRAS HRAS CBL
46
Show member pathways
12.18 NRAS KRAS JAK2 HRAS FLT3 CBL
47 12.15 NRAS KRAS JAK2 HRAS
48
Show member pathways
12.12 NRAS KRAS JAK2 HRAS
49
Show member pathways
12.12 NRAS KRAS JAK2 HRAS
50
Show member pathways
12.11 KRAS JAK2 HRAS CBL

GO Terms for Core Binding Factor Acute Myeloid Leukemia

Cellular components related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 WT1 TLE1 RUNX2 RUNX1 JAK2 HRAS
2 membrane raft GO:0045121 9.26 KRAS JAK2 CBL ABCG2
3 core-binding factor complex GO:0016513 8.62 RUNX1 CBFB

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 TLE1 NRAS KRAS KIT JAK2 HRAS
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 WT1 RUNX2 RUNX1 HRAS CSF3 CEBPA
3 regulation of transcription by RNA polymerase II GO:0006357 10.09 WT1 RUNX2 RUNX1 KIT CEBPA CBFB
4 negative regulation of cell proliferation GO:0008285 9.98 WT1 JAK2 HRAS CSF1R CEBPA
5 positive regulation of cell migration GO:0030335 9.94 KIT JAK2 HRAS CSF1R
6 positive regulation of gene expression GO:0010628 9.91 WT1 TLE1 RUNX2 KRAS KIT HRAS
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 KIT JAK2 CSF3
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.86 NRAS KRAS HRAS
9 male gonad development GO:0008584 9.85 WT1 KIT CBL
10 ossification GO:0001503 9.85 RUNX2 RUNX1 CBFB
11 protein autophosphorylation GO:0046777 9.85 KIT JAK2 FLT3 CSF1R
12 liver development GO:0001889 9.83 KRAS HRAS CEBPA
13 positive regulation of kinase activity GO:0033674 9.8 KIT FLT3 CSF1R
14 hematopoietic progenitor cell differentiation GO:0002244 9.8 KIT FLT3 CSF1R
15 peptidyl-tyrosine phosphorylation GO:0018108 9.8 KIT JAK2 FLT3 CSF1R
16 MAPK cascade GO:0000165 9.8 NRAS KRAS KIT JAK2 HRAS FLT3
17 Ras protein signal transduction GO:0007265 9.79 NRAS KRAS HRAS
18 cellular response to cytokine stimulus GO:0071345 9.77 FLT3 CSF3 CSF1R
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 KIT JAK2 FLT3 CSF1R
20 positive regulation of MAP kinase activity GO:0043406 9.71 KRAS KIT HRAS FLT3
21 regulation of keratinocyte differentiation GO:0045616 9.69 RUNX1 CBFB
22 cell maturation GO:0048469 9.69 RUNX2 CEBPA CBFB
23 regulation of regulatory T cell differentiation GO:0045589 9.68 RUNX1 CBFB
24 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.68 RUNX1 CBFB
25 regulation of bicellular tight junction assembly GO:2000810 9.67 RUNX1 CBFB
26 mast cell degranulation GO:0043303 9.66 KIT CBL
27 positive regulation of phospholipase C activity GO:0010863 9.66 KIT HRAS
28 regulation of B cell receptor signaling pathway GO:0050855 9.65 RUNX1 CBFB
29 regulation of myeloid cell differentiation GO:0045637 9.65 RUNX1 CBFB
30 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 KIT JAK2 FLT3 CSF3 CBL
31 granulocyte differentiation GO:0030851 9.64 CSF3 CEBPA
32 lymphocyte differentiation GO:0030098 9.63 FLT3 CBFB
33 interleukin-6-mediated signaling pathway GO:0070102 9.63 JAK2 CEBPA CBL
34 regulation of cytokine-mediated signaling pathway GO:0001959 9.61 RUNX1 CBFB
35 response to isolation stress GO:0035900 9.6 KRAS HRAS
36 regulation of signaling GO:0023051 9.58 MVP CBL
37 myeloid progenitor cell differentiation GO:0002318 9.57 KIT FLT3
38 positive regulation of cell proliferation GO:0008284 9.56 RUNX2 KRAS KIT JAK2 HRAS FLT3
39 hemopoiesis GO:0030097 9.55 RUNX2 RUNX1 KIT FLT3 CSF1R
40 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.54 RUNX1 CBFB
41 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.52 RUNX1 CBFB
42 cytokine-mediated signaling pathway GO:0019221 9.23 KRAS KIT JAK2 FLT3 CSF3 CSF1R

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.22 WT1 TLE1 RUNX2 RUNX1 NRAS MVP
2 ATP binding GO:0005524 9.98 RUNX2 RUNX1 KIT JAK2 FLT3 CSF1R
3 nucleotide binding GO:0000166 9.86 NRAS KRAS KIT JAK2 HRAS FLT3
4 transcription regulatory region DNA binding GO:0044212 9.71 WT1 RUNX2 RUNX1 CEBPA
5 GDP binding GO:0019003 9.54 NRAS KRAS HRAS
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KIT FLT3 CSF1R
7 growth factor binding GO:0019838 9.13 KIT FLT3 CSF1R
8 protein tyrosine kinase activity GO:0004713 8.92 KIT JAK2 FLT3 CSF1R

Sources for Core Binding Factor Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....